• Eric A Leslie, Jennifer Byrne, Paula Mesarwi, Kyle P Edmonds, Jeremy M Hirst, and Rabia S Atayee.
• UC San Diego & Scripps Health Joint Fellowship in Hospice & Palliative Medicine, Department of Family Medicine, UC San Diego Health Sciences, La Jolla, California, USA.
• J Palliat Med. 2024 Oct 1; 27 (10): 130313091303-1309.

AbstractContext: Pain and symptom management at the end of life (EoL) can pose unique challenges, particularly when symptoms are refractory to conventional methods. Dexmedetomidine, originally approved for sedation in ventilated patients, has been demonstrated to be beneficial in pain management and palliative care settings by functioning as an alpha-2 agonist. Methods: A retrospective review of inpatient palliative care unit (IPU) records from January 2020 to December 2023 was conducted. Twenty-five adult patients receiving continuous dexmedetomidine for refractory pain at the EoL were identified. These patients were further evaluated for concurrent opioid, benzodiazepine, and chlorpromazine usage. Results: Patients experienced predominantly cancer-related pain, and had a median infusion duration of 5 days. Dexmedetomidine's initial dosing differed between the intensive care unit (ICU) and IPU settings. There was a trend toward a decreased opioid requirement 24 hours after initiation. Patients transferred from the ICU showed a progressive increase in opioid use. Conclusion: This study contributes to understanding dexmedetomidine's role in managing refractory symptoms at the EoL in the palliative care setting.

29 keywords...

hide…